A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
NCT06373146 on ClinicalTrials.gov · last registry update 2026-05-06
An unusually large phase 2: 392 participants, more than double the 114 typical for the stage. The sponsor logged completion for 15 December 2025. Primary outcome, as filed: Mean Percent Change from Baseline in Body Weight. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P2
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 392
- Started
- 2024-04-24
- Primary completion
- 2025-12-15 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Mean Percent Change from Baseline in Body Weight
Conditions studied
Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.